44 results about "Tongue squamous cell carcinoma" patented technology

The invention provides a novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof and particularly relates to application of a KLK14 gene and an expression product thereof to diagnosis and treatment of tongue squamous carcinoma. To research the occurrence and development mechanisms of tongue squamous carcinoma, search for an effective molecular target gene for diagnosing and treating tongue squamous carcinoma, promote early diagnosis, prevention and treatment of the disease and lower the death rate of tongue cancer, firstly, RNA-seq sequencing is utilized to detect differential expression genes of tongue squamous carcinoma, cancer branch and normal oral mucosa; secondly, a Real-time PCR technology is utilized to verify the sequencing result; then, an interference technology is utilized, and expression of the candidate gene KLK14 in tongue squamous carcinoma cells SCC15 is silenced. By means of the novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof, an experimental foundation is laid for clinical application of the KLK14 gene to tongue squamous carcinoma, and a new target gene and theoretical basis are provided for early diagnosis and treatment of tongue squamous carcinoma.

The invention provides genes highly expressed in the tongue squamous carcinoma para-carcinoma tissue and applications of the genes, and in particular relates to the LCE3E gene and the GSDMA gene and applications of expression products of the LCE3E gene and the GSDMA gene in diagnosing tongue squamous carcinoma and preparing biological medicines for treating tongue squamous carcinoma. According to the invention, based on the high-throughput sequencing and in combination with the molecular biology experiment, the screened molecular diagnosis and treatment markers, namely, the LCE3E gene and the GSDMA gene for tongue squamous carcinoma are verified, therefore, an experimental foundation is provided for the clinical applications of the LCE3E gene and the GSDMA gene in tongue squamous carcinoma, and thus a novel target gene is provided for the early diagnosis and treatment of tongue squamous carcinoma.

The invention discloses a gene BPIFB1 and an expression product thereof. The gene BPIFB1 is a molecular marker for tongue squamous cell carcinoma early diagnosis. The gene BPIFB1 and the expression product have the advantages that as proved by QPCR (quantitative polymerase chain reaction), the gene BPIFB1 can be differently expressed in tongue squamous cell carcinoma tissues and para-carcinoma tissues and can be used as an indicator for tongue squamous cell carcinoma early diagnosis; the gene BPIFB1 and the expression product can be used as targets for treating tongue squamous cell carcinoma and can be used for guiding research and development of new medicines.

The invention discloses shRNA for inhibiting human EDARADD gene expression, a lentiviral vector and a construction method and application of the lentiviral vector. The method comprises the following steps: firstly, synthesizing a positive strand and a negative strand of DNA oligo aiming at an RNA interference target sequence; annealing the positive strand and the negative strand to form double-stranded DNA with a cohesive end; linearizing the lentiviral vector through enzyme digestion, and connecting the linearized vector with double-stranded DNA; transforming escherichia coli competent cellswith a connection product, and carrying out PCR identification on the obtained positive clone; and performing plasmids extraction for virus packaging in the next step. According to the invention, theRNA interference target sequence is designed by taking an EDARADD gene as a template, an shRNA interference sequence is designed according to a selected target sequence, an RNA interference lentiviralvector is constructed through packaging, and after the EDARADD gene is knocked down, proliferation of tongue squamous cell carcinoma cells CAL-27 can be remarkably influenced, the cell clone formingcapacity is influenced, and cell apoptosis is promoted.

The invention discloses a CDSN gene as a diagnosis and treatment target of tongue squamous carcinoma. By detecting content of CDSN gene and its expression product in tissues of a subject, whether the subject is affected with tongue squamous carcinoma can be judged or whether the subject has the risk of suffering from tongue squamous carcinoma can be diagnosed, or a patient's reactivity to drug therapy can be judged, or a patient's relapse and prognosis can be judged. In addition, through the research on proliferation index of tongue squamous carcinoma cells cultured in vitro, it is proved that the CDSN gene and its expression production are used as the drug target for treatment of tongue squamous carcinoma.

The invention discloses an antisense oligonucleotide for inhibiting miR-21 expression in the tongue squamous cell carcinoma and its application. The antisense oligonucleotide of the invention comprises complementary sequences with at least 12 continuous nucletides in nucleotide sequences as below: 5'-UAGCUUAUCAGACUGAUGUUGA-3', and said complementary sequences can specifically bind with different regions of human miR-21. The antisense oligonucleotide of the invention can be a ribonucleotide or a deoxyribonucleotide and modify any nucleotide. The miR-21 antisense oligonucleotide with anti-tongue squamous cell carcinoma action of the invention can effectively inhibit the expression of the miR-21 in the tongue squamous cell carcinoma cell SSC-15 and CAL-27, simultaneously inhibit said two cells growth and proliferation, promote the apoptosis, thereby effectively treating the tongue squamous cell carcinoma and other miR-21 high expression tumors.

The invention belongs to the field of the biopharmaceutical research, and particularly relates to application of a MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+dependent)1like) inhibitor. Bywide and deep research, the invention shows that MTHFD1L can be used as a tongue squamous cell carcinoma treatment target for the first time. The MTHFD1L inhibitor can inhibit cell multiplication oftongue squamous cell carcinoma, promote cell apoptosis of tongue squamous cell carcinoma, inhibit cell cloning, inhibit tumorigenesis of tongue squamous cell carcinoma, treat tongue squamous cell carcinoma and develops a new direction for treatment of tongue squamous cell carcinoma.

The invention discloses application of a reagent capable of promoting circular RNA (Ribonucleic Acid) circRNF13 expression to preparation of a medicine for treating tongue squamous cell carcinoma. A research proves that circRNF13 is overexpressed in tongue squamous cell carcinoma cells and the proliferation of the tongue squamous cell carcinoma cells can be inhibited. Therefore, a circRNF13 overexpression preparation is used for treating the tongue squamous cell carcinoma and has profound clinical significance and an important popularization and application prospect.

The invention discloses a series of oligonucleotides; in fluorescent real-time quantitative PCR reaction, the oligonucleotides can specifically detect the expression of miR-21. On the basis, the invention uses the oligonucleotides to prepare reagents with highly expressed miR-21 for diagnosis, aging and prognosis evaluation of tongue squamous carcinoma. The invention further discloses a kit containing the oligonucleotides, and the kit can be used for diagnosis, aging and prognosis evaluation of tongue squamous carcinoma.

The invention discloses ANKRD1 as a diagnosis and treatment target of tongue squamous cell carcinoma. Accordingly, ANKRD1 can be used for developing tongue squamous cell carcinoma diagnosis products and tongue squamous cell carcinoma treatment drugs. By means of research results, theoretical basis is provided for personalized treatment plan making by clinicians, and the novel drug target can be provided for development of the tongue squamous cell carcinoma treatment drugs.

The present invention relates to the technical fields of molecular biology and biomedicine, and particularly relates to a molecular marker for preventing, diagnosing and treating tongue squamous cellcarcinoma, and an application thereof. The disclosed molecular marker for preventing, diagnosing and treating the tongue squamous cell carcinoma is LncRNA DANCR. The molecular marker is applied in screening or preparing reagents for diagnosing tongue squamous cell carcinoma and screening or preparing medicines for treating tongue squamous cell carcinoma. The LncRNA DANCR is found to be highly expressed in tongue squamous cell carcinoma tissues and an independent indicator for diagnosing tongue squamous cell carcinoma and judging progression and survival prognosis of tongue squamous cell carcinoma. Besides, silencing LncRNA DANCR can inhibit proliferation, cell migration and invasion of tongue squamous cell carcinoma in vitro. The LncRNA DANCR is confirmed for the first time as an importantoncogenic factor for tongue squamous cell carcinoma and can be used as the molecular marker for tongue squamous cell carcinoma diagnosis and a new target for treatment.

The invention discloses a genetic marker. The genetic marker is ACTA1. ACTA1 can be used for determining whether a subject has a risk of suffering from the tongue squamous cell carcinoma or not or determining whether the subject suffers from the tongue squamous cell carcinom or not. In addition, ACTA1 also can be used for preparing drugs for treatment of the tongue squamous cell carcinoma. The invention provides a new diagnostic method for clinical diagnosis of the tongue squamous cell carcinoma at the molecular level and further provides a new drug target for gene therapy of the tongue squamous cell carcinoma.

The invention discloses a tongue squamous carcinoma diagnosis and treatment target-AMTN gene. Whether asubject suffers from the tongue squamous carcinoma or not can be judged or whether the risk that asubject suffers from the tongue squamous carcinomaexists or not can be diagnosed by detecting the AMTN gene in the bone marrow tissue of the subject and the content of it expression product. In addition, it is proved through research on proliferationindexes of tongue squamous carcinoma cells cultured in vitro that the AMTN gene is used as a drug target for treating the tongue squamous carcinoma.

The invention discloses a preparation method and application of bacterial wall-modified liposome-loaded doxorubicin, which comprises dissolving soybean lecithin, cholesterol and doxorubicin in an organic solvent and rotary evaporation to obtain a dry lipid film ; The lipid film is hydrated, and the bacterial wall is added while hydrating to obtain DOX‑BW‑LP; the bacterial wall is the bacterial wall of Staphylococcus aureus. In the present invention, bacterial wall fusion liposomes are prepared into immunoliposomes, which act on human tongue squamous cell carcinoma cells, and it is found that the bacterial wall of Staphylococcus aureus prepared by the present invention has an immunoregulatory effect on macrophages, and induces macrophages to M1 polarization can enhance the recognition and phagocytosis of macrophages on tumor cells, and realize the functions of killing tumors and inhibiting tumor growth. The multiple roles of tumors provide new ideas for immunotherapy of oral cancer.

The invention discloses a PNLIPRP3 gene which can be adopted as a molecular marker for tongue squamous carcinoma diagnosis and treatment. Experiments show that compared with normal tissue, the PNLIPRP3 gene is low in expression quantity in tongue squamous carcinoma tissue. The invention further discloses application of the PNLIPRP3 gene for preparing a drug for tongue squamous carcinoma treatment. The invention provides a novel tongue squamous carcinoma clinic treatment method, and further provides a novel drug target for tongue squamous carcinoma treatment.

The invention discloses application of a reagent for detecting ring-shaped RNA (ribonucleic acid) circRNF13 in preparing a tongue squamous carcinoma auxiliary diagnosis preparation, and particularly relates to a preparation for auxiliary diagnosis of tongue squamous carcinoma through a real-time fluorescence quantification analysis method. The research proves that the expression of circRNF13 in tongue squamous carcinoma tissue is down-regulated. Therefore, the expression situation of the circRNF13 is used for the auxiliary diagnosis of the tongue squamous carcinoma and has far-reaching clinical significance and important popularization and application prospects.

The invention discloses application of a reagent for detecting cyclic RNA circRNF13 in preparing a prognosis preparation for tongue squamous cell carcinoma patients, in particular to a preparation forprognosis of the tongue squamous cell carcinoma patients by using a real-time fluorescence quantitative analysis method. The survival analysis of the expression of the circRNF13 in tongue squamous cell carcinoma tissues and the survival time and status of the patients shows that the average survival time of patients who do not express the circRNF13 in the tongue squamous cell carcinoma tissues issignificantly shorter than that of patients with higher expression of the circRNF13. The circRNF13 is a molecular marker associated with the prognosis of the tongue squamous cell carcinoma; the circRNF13 is low in expression or is not expressed, which causes poor prognosis of the patients.

The invention discloses application of a reagent for detecting cyclic RNA circRNF13 in preparing a prognosis preparation for tongue squamous cell carcinoma patients, in particular to a preparation forprognosis of the tongue squamous cell carcinoma patients by using a real-time fluorescence quantitative analysis method. The survival analysis of the expression of the circRNF13 in tongue squamous cell carcinoma tissues and the survival time and status of the patients shows that the average survival time of patients who do not express the circRNF13 in the tongue squamous cell carcinoma tissues issignificantly shorter than that of patients with higher expression of the circRNF13. The circRNF13 is a molecular marker associated with the prognosis of the tongue squamous cell carcinoma; the circRNF13 is low in expression or is not expressed, which causes poor prognosis of the patients.

The invention discloses application of a reagent capable of promoting circular RNA (Ribonucleic Acid) circRNF13 expression to preparation of a medicine for treating tongue squamous cell carcinoma. A research proves that circRNF13 is overexpressed in tongue squamous cell carcinoma cells and the proliferation of the tongue squamous cell carcinoma cells can be inhibited. Therefore, a circRNF13 overexpression preparation is used for treating the tongue squamous cell carcinoma and has profound clinical significance and an important popularization and application prospect.

The invention discloses a Chinese medicinal compound with a tongue squamous cell carcinoma resisting effect and a preparation method thereof. The Chinese medicinal compound is prepared from the following raw materials in parts by weight: 10-20 parts of waxgourd seed, 12-24 parts of rhizoma pinellinae praeparata, 10-20 parts of arisaema cum bile, 12-24 parts of indian iphigenia bulb, 10-20 parts of ternate buttercup root, 10-20 parts of wild buckwheat rhizome, 10-20 parts of heartleaf houttuynia herb, 15-30 parts of hairyvein agrimonia herb and bud, 12-24 parts of sappan wood, 15-30 parts of safflower, 10-20 parts of straight ladybell root, 10-20 parts of fragrant solomonseal rhizome and 10-20 parts of dwarf lilyturf root. The Chinese medicinal compound with the tongue squamous cell carcinoma resisting effect provided by the invention is prepared by selecting raw materials according to the traditional Chinese medicine theory and the pathogenesis of tongue squamous cell carcinoma, and components are blended scientifically and reasonably; and as proved by a pharmacodynamics experiment result, the Chinese medicinal compound can contribute to remarkably lowering the content of PGE2, has a very good tongue squamous cell carcinoma resisting effect, is free from untoward effects after long-term use, and can be developed into a new generation of tongue squamous cell carcinoma resisting medicament.

The invention discloses an application method of annular RNAcircRNF13, and particularly relates to an application of an overexpression circRNF13 preparation in preparing a preparation for reducing thedrug resistance of tongue squamous cell carcinoma cells to cis-platinum drugs. The research proves that the circRNF13 is over-expressed in the tongue squamous carcinoma drug-resistant cells, so thatthe drug resistance of the tongue squamous carcinoma cells can be apparently reversed. Therefore, the circRNF13 overexpression preparation is used for reducing the drug resistance of the tongue squamous carcinoma cells and has the profound clinical significance and important popularization and application prospect.

The invention belongs to the field of biomedical research, and particularly relates to application of a human DEPDC1 gene as a target in preparation of tongue squamous cell carcinoma treatment drugs or tongue squamous cell carcinoma diagnosis drugs. Through wide and deep research, it is found that proliferation of tongue squamous cell carcinoma cells can be effectively inhibited and cell apoptosisis promoted after expression of a human DEPDC1 gene is lowered through an RNAi method, so that the growth process of tongue squamous cell carcinoma can be effectively controlled. The siRNA or the nucleic acid construct containing the siRNA sequence and the lentivirus provided by the invention can specifically inhibit the proliferation rate of tongue squamous cell carcinoma cells, promote apoptosis of the tongue squamous cell carcinoma cells, inhibit cloning of the tongue squamous cell carcinoma cells, influence the period of the tongue squamous cell carcinoma cells and inhibit growth of the tongue squamous cell carcinoma cells, so that the tongue squamous cell carcinoma is treated, and a new direction is opened up for tongue squamous cell carcinoma treatment.

The invention provides a novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof and particularly relates to application of a KLK14 gene and an expression product thereof to diagnosis and treatment of tongue squamous carcinoma. To research the occurrence and development mechanisms of tongue squamous carcinoma, search for an effective molecular target gene for diagnosing and treating tongue squamous carcinoma, promote early diagnosis, prevention and treatment of the disease and lower the death rate of tongue cancer, firstly, RNA-seq sequencing is utilized to detect differential expression genes of tongue squamous carcinoma, cancer branch and normal oral mucosa; secondly, a Real-time PCR technology is utilized to verify the sequencing result; then, an interference technology is utilized, and expression of the candidate gene KLK14 in tongue squamous carcinoma cells SCC15 is silenced. By means of the novel target gene for diagnosing and treating tongue squamous carcinoma and application thereof, an experimental foundation is laid for clinical application of the KLK14 gene to tongue squamous carcinoma, and a new target gene and theoretical basis are provided for early diagnosis and treatment of tongue squamous carcinoma.

The invention provides application of long non-coding RNA (Ribonucleic Acid) in diagnosis and treatment of tongue squamous cell carcinoma, and belongs to the technical field of crude drugs and molecular biology. It is proved for the first time that LINC01356 expression is increased along with increase of tongue squamous cell carcinoma malignancy degree and is in negative correlation with the survival rate. After the expression of the LINC01356 is interfered, the proliferation of tongue squamous carcinoma cells is inhibited, the apoptosis of the tongue squamous carcinoma cells is promoted, and the LINC01356 can be used as an effective medicine for preventing and / or treating the tongue squamous carcinoma. The invention provides a more favorable means for diagnosis and prognosis evaluation analysis of tongue squamous cell carcinoma, which is of great significance for research and treatment of tongue squamous cell carcinoma. Meanwhile, an experimental foundation is laid for developing high-efficiency related medicines for treating tongue squamous cell carcinoma, and a new view field is provided, so that the application has a good practical application value.

The invention discloses a shRNA, a lentiviral vector and its construction method and application for inhibiting the expression of human EDARADD gene. Firstly, the forward strand and the reverse strand of the DNA oligo aiming at the RNA interference target sequence are synthesized; the forward strand and the reverse strand are annealed to form a band Double-stranded DNA at the cohesive end; linearize the lentiviral vector by enzyme digestion, connect the linearized vector to the double-stranded DNA; transform the ligated product into E. coli competent cells, and perform PCR identification on the positive clones obtained; plasmid extraction, For the next step of virus packaging. The present invention uses the EDARADD gene as a template to design the RNA interference target sequence, designs the shRNA interference sequence according to the selected target sequence, packages and constructs the RNA interference lentiviral vector, and knocks down the EDARADD gene, which will significantly affect the CAL of tongue squamous cell carcinoma cells Proliferation of ‑27 cells, affecting cell clone formation ability, and promoting cell apoptosis.

The invention belongs to the field of biological medicines, and discloses application of a GAGE2D gene used as a diagnosis and treatment marker for tongue squamous carcinoma. An experiment provided by the invention proves that the expression of the GAGE2D gene in normal tissues is significantly different from that in tongue squamous carcinoma tissues. According to the correlation between the GAGE2D gene and the tongue squamous carcinoma, the GAGE2D gene can be used as a novel molecular marker for clinically diagnosing the tongue squamous carcinoma, and can also be used as a novel target of a medicine for treating the tongue squamous carcinoma at the same time.

The invention belongs to the field of the biopharmaceutical research, and particularly relates to application of a MTHFD1L (methylenetetrahydrofolate dehydrogenase (NADP+dependent)1like) inhibitor. Bywide and deep research, the invention shows that MTHFD1L can be used as a tongue squamous cell carcinoma treatment target for the first time. The MTHFD1L inhibitor can inhibit cell multiplication oftongue squamous cell carcinoma, promote cell apoptosis of tongue squamous cell carcinoma, inhibit cell cloning, inhibit tumorigenesis of tongue squamous cell carcinoma, treat tongue squamous cell carcinoma and develops a new direction for treatment of tongue squamous cell carcinoma.

The invention discloses a PNLIPRP3 gene which can be adopted as a molecular marker for tongue squamous carcinoma diagnosis and treatment. Experiments show that compared with normal tissue, the PNLIPRP3 gene is low in expression quantity in tongue squamous carcinoma tissue. The invention further discloses application of the PNLIPRP3 gene for preparing a drug for tongue squamous carcinoma treatment. The invention provides a novel tongue squamous carcinoma clinic treatment method, and further provides a novel drug target for tongue squamous carcinoma treatment.

The invention discloses a genetic marker. The genetic marker is ACTA1. ACTA1 can be used for determining whether a subject has a risk of suffering from the tongue squamous cell carcinoma or not or determining whether the subject suffers from the tongue squamous cell carcinom or not. In addition, ACTA1 also can be used for preparing drugs for treatment of the tongue squamous cell carcinoma. The invention provides a new diagnostic method for clinical diagnosis of the tongue squamous cell carcinoma at the molecular level and further provides a new drug target for gene therapy of the tongue squamous cell carcinoma.